During the trial, palbociclib — a pill — was combined with the standard anti-estrogen treatment Letrozole. The combined treatment resulted in a 26.1 month progression-free survival rate compared with only 7.5 months for Letrozole alone. Under development by Pfizer Inc. (NYSE:PFE), the medication used in the study is a selective inhibitor of cyclin-dependent kinases (CDK) 4 and 6. Pfizer Inc. (NYSE:PFE) stock performance was -1.06% in last session and finished the day at $30.87. Traded volume was 34.57million shares in the last session and the average volume of the stock remained 27.71million shares. The beta of the stock remained 0.64. Pfizer Inc. (NYSE:PFE) insider ownership is 0.10%.
Express Scripts Holding Co., a pharmacy benefits manager that handles more than 1 billion prescriptions a year in the U.S., is ratcheting up its effort to force Gilead Sciences Inc. (NASDAQ:GILD) to cut the $84,000 price of its new hepatitis C pill Sovaldi. Gilead Sciences, Inc. (NASDAQ:GILD) dropped -3.07 percent to $70.01 Tuesday on volume of 25.27million shares. The intra-day range of the stock was $69.28 to $71.71. Gilead Sciences, Inc. (NASDAQ:GILD) has a market capitalization of $107.67billion.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) said Tuesday it is now selling a generic version of the heart medication Lovaza, which is used to treat high triglyceride levels. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)’s stock on Apr 08, 2014 reported a decrease of -1.18% to the closing price of $50.90. Its fifty two weeks range is $36.26 -$54.70. The total market capitalization recorded $48.31billion. The overall volume in the last trading session was 12.30million shares. In its share capital, TEVA has 955.87million outstanding shares.
Scientists from Bristol-Myers Squibb Co (NYSE:BMY) have developed a novel approach for the simultaneous quantitation of neutralizing antibodies, residual drug, and human Immunoglobulin G (IgG) in immunogenicity assay development using liquid chromatography–tandem mass spectrometry (LC–MS–MS). On Tuesday, shares of Bristol-Myers Squibb Co (NYSE:BMY) dropped -2.43% to close the day at $49.06. Company return on investment (ROI) is 10.70% and its monthly performance is recorded as -12.00%. Bristol-Myers Squibb Co (NYSE:BMY) quarterly revenue growth is -6.02%.